A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

Launched by PFIZER · Feb 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Zavicefta to find out how safe and effective it is for treating certain serious infections after it becomes available in Korea. The infections being looked at include complicated infections in the abdomen, urinary tract infections, and pneumonia that patients may have contracted while in the hospital. The goal is to gather important information about Zavicefta’s performance in real-world settings, which is required by Korean health regulations.

Eligibility for this trial includes adults and children aged 3 months and older who have received at least one dose of Zavicefta for the specified infections. Participants must also be receiving Zavicefta for the first time and agree to share their health data while maintaining privacy. If you or someone you know qualifies and decides to participate, you can expect to receive the medication as part of their treatment and contribute to valuable research that helps understand its use in different patient populations.

Gender

ALL

Eligibility criteria

• 1. Adults and paediatric patients aged 3 months and older, who have been administered at least one dose of Zavicefta for the treatment of one of the indications as follows:
• • Complicated intra-abdominal infection (cIAI)
• • Complicated urinary tract infection (cUTI), including pyelonephritis
• • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
• • Other aerobic Gram-negative organism infection with limited treatment options
• 2. Adults 19 years of age or older, who have been administered at least one dose of Zavicefta for the treatment of the indication as follows:
• • •Bacteremia associated with or suspected to be associated with cIAI, cUTI or HAP including VAP.
• • 3. Patients are treated with Zavicefta for the first time
• • 4. Patients have signed the data privacy statement.